Posts Tagged ‘HDL-C’

RSS

September 23rd, 2013

HDL-P: The Better Marker of Residual Risk?

CardioExchange Editors interview Samia Mora about her investigative group’s analysis of data from the JUPITER trial, which reveals that HDL-P may be a better marker of residual risk than chemically measured HDL-C or apoA-1.


August 13th, 2012

Selections from Richard Lehman’s Literature Review: August 13th

This week’s topics include using existing data for new research; normal weight, diabetes, and non-CVD death; cholesterol levels in U.S. kids; statins and diabetes; HDL-C and MI protection; statin treatment; hypertension treatment; clopidogrel and PPIs; and an analysis behind the “innovation crisis” of the pharmaceutical industry.


May 21st, 2012

Selections from Richard Lehman’s Literature Review: Week of May 21st

This week’s topics include warfarin vs. aspirin for stroke prevention in HF, CVD risks and azithromycin, coffee’s benefits, the old news that statins work, the question of HDL-C, abdominal aortic aneurysm, omega-3 fatty acid supplements, and Abbott’s methods for staying ahead with fenofibrate prescriptions.